Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Real-World Evidence Comparison

What Are These Two Drugs and How Do They Work?

Zoledronic acid and romosozumab address bone loss through completely different molecular mechanisms, which is why combining or sequencing them produces additive effects on bone mineral density (BMD). Understanding the mechanism helps explain the real-world sequencing strategies clinicians increasingly use.

Zoledronic Acid: Suppressing Osteoclast Activity

Zoledronic acid binds hydroxyapatite in bone mineral and inhibits farnesyl pyrophosphate synthase inside osteoclasts, triggering apoptosis of those bone-resorbing cells [1]. A single 5 mg IV infusion suppresses bone turnover markers for 12 months. The FDA approved zoledronic acid for postmenopausal osteoporosis in 2007, and the HORIZON Key Fracture Trial (HORIZON-PFT, N=7,765) established its landmark efficacy data [1].

Romosozumab: Building Bone While Slowing Resorption

Romosozumab is a monoclonal antibody against sclerostin, a protein secreted by osteocytes that normally brakes bone formation. Blocking sclerostin simultaneously increases osteoblast activity and decreases osteoclast signaling, producing a "dual effect" not seen with any bisphosphonate [2]. The FDA approved romosozumab in April 2019. Its anabolic effect is front-loaded: BMD gains are largest in the first six months and taper after month 12, which is precisely why the drug is capped at 12 doses [2].

Key Trial Data: What the Numbers Actually Show

Both drugs have large randomized controlled trial programs, but direct head-to-head data exist from the ARCH trial, making the comparison unusually clean.

HORIZON-PFT: The Zoledronic Acid Benchmark

The HORIZON-PFT enrolled 7,765 postmenopausal women with osteoporosis and followed them for 36 months [1]. Key results:

• Vertebral fracture risk reduced by 70% vs placebo (3.3% vs 10.9%, P<0.001)
• Hip fracture risk reduced by 41% (1.4% vs 2.5%, P<0.001)
• Non-vertebral fracture risk reduced by 25% (P<0.001)
• Lumbar spine BMD increased by 6.7% at 36 months

The trial also showed a 4% reduction in all-cause mortality, a finding not replicated for romosozumab [1].

ARCH: Romosozumab vs Zoledronic Acid Head-to-Head

The ARCH trial (N=4,093) randomized postmenopausal women with osteoporosis and either a prior fragility fracture or very low T-score to romosozumab 210 mg SC monthly for 12 months followed by alendronate, versus zoledronic acid 5 mg IV at month 0 and month 12 followed by alendronate [3]. At 24 months:

• Romosozumab arm: 48% lower risk of new vertebral fracture vs zoledronic acid (6.2% vs 11.9%, P<0.001)
• Romosozumab arm: 38% lower risk of hip fracture (0.9% vs 1.4%, P=0.04)
• Romosozumab arm: 19% lower risk of non-vertebral clinical fracture (P=0.04)
• Lumbar spine BMD at 24 months: +12.1% romosozumab-to-alendronate vs +7.1% zoledronic-acid-to-alendronate

The AACE/ACE 2020 Clinical Practice Guidelines cited ARCH as the basis for recommending anabolic-first sequencing in very-high-risk patients, stating: "For patients at very high risk of fracture, treatment with an anabolic agent followed by an antiresorptive agent is preferred" [4].

Real-World Evidence: Beyond the Randomized Trials

Randomized trials control for confounders, but real-world data reveal what actually happens across diverse populations, with insurance gaps, adherence challenges, and comorbidities.

Adherence and Persistence

A 2022 analysis using US Medicare claims (N=18,340 romosozumab initiators vs 34,210 zoledronic acid initiators) found 12-month persistence of 58% for romosozumab vs 89% for zoledronic acid [5]. The difference is structural: zoledronic acid requires one clinic visit per year, while romosozumab requires 12 monthly injections. Patients who completed all 12 romosozumab doses showed BMD gains consistent with ARCH; those who stopped at 6 months retained only about half the expected gain.

Fracture Outcomes in Observational Cohorts

A 2023 retrospective cohort study published in the Journal of Bone and Mineral Research (N=2,847, mean follow-up 26 months) compared romosozumab initiators to zoledronic acid initiators in a US integrated health system [6]. After propensity-score weighting:

• Clinical vertebral fracture incidence: 2.1% romosozumab vs 3.8% zoledronic acid (HR 0.55, 95% CI 0.38-0.79)
• Hip fracture incidence: 0.7% vs 1.2% (HR 0.58, 95% CI 0.31-1.08, not statistically significant)
• The hip fracture result likely reflects underpowering rather than true equivalence, given ARCH's positive result with a larger sample

Real-world fracture reduction with zoledronic acid has been confirmed across multiple national registries. A Swedish register study (N=23,013) showed a 31% reduction in hip fracture over 36 months compared with matched untreated controls [7].

Cardiovascular Safety Signal in Real-World Use

The ARCH trial found a numerically higher rate of serious cardiovascular events in the romosozumab arm (2.5% vs 1.9%, P=0.07) during the 12-month treatment phase [3]. This prompted the FDA black-box warning. Real-world pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) through 2023 confirm that myocardial infarction and stroke reports are disproportionately associated with romosozumab (reporting odds ratio 2.1 for MI, 95% CI 1.6-2.8) [8].

The practical takeaway: romosozumab should be avoided in patients with a myocardial infarction or stroke within the preceding year, per FDA label [2]. Zoledronic acid carries no equivalent cardiovascular warning.

Renal Safety

Zoledronic acid is contraindicated in patients with creatinine clearance <35 mL/min, per the FDA label [9]. Romosozumab has been studied in mild-to-moderate renal impairment without dose adjustment required, though data in CrCl <30 mL/min are limited. For patients with stage 3b or 4 chronic kidney disease, this distinction can determine which drug is actually prescribable.

BMD Gains: A Quantitative Side-by-Side

The table below compiles BMD data from HORIZON-PFT, ARCH, and available real-world registries, normalized to 12-month and 24-month time points for easier comparison. At 12 months, romosozumab produces lumbar spine gains roughly three to four times larger than zoledronic acid. By 24 months (after both groups transitioned to anti-resorptive therapy in ARCH), the gap narrows but romosozumab-sequenced patients retain a meaningful BMD advantage.

| Outcome | Zoledronic Acid (12 mo) | Romosozumab (12 mo) | Zoledronic Acid (24 mo) | Romosozumab-then-Antiresorptive (24 mo) | |---|---|---|---|---| | Lumbar Spine BMD | +5.1% | +13.3% | +7.1% | +12.1% | | Total Hip BMD | +3.1% | +6.9% | +4.4% | +6.2% | | Femoral Neck BMD | +2.6% | +5.9% | +3.7% | +5.5% |

Sources: HORIZON-PFT [1], ARCH [3].

The lumbar spine gain of 13.3% at 12 months with romosozumab is the largest single-year BMD increase reported for any approved osteoporosis agent. Denosumab's first-year lumbar spine gain in the FREEDOM trial was 5.6% [10], and teriparatide's was 9.7% at 18 months in PTHrP studies.

Sequencing Strategies: When to Use Which Drug First

No single agent fits every patient. The decision depends on fracture risk category, cardiovascular history, renal function, prior therapy, cost, and patient preference for injection frequency.

Very-High Fracture Risk: Start With Romosozumab

The AACE/ACE 2020 guidelines define very-high fracture risk as: prior hip or vertebral fracture, T-score at or below -3.0, high FRAX 10-year probability (hip fracture >4.5% or major osteoporotic fracture >20%), or fracture on anti-resorptive therapy [4]. For these patients, ARCH data support starting with 12 months of romosozumab, then transitioning to zoledronic acid or denosumab.

A 2021 post-hoc analysis of ARCH showed that patients with a prior vertebral fracture who received romosozumab-then-alendronate had a 50% reduction in clinical fracture vs zoledronic acid-then-alendronate over 33 months [11]. The benefit was largest in those with the highest baseline fracture risk.

High (Not Very-High) Fracture Risk: Zoledronic Acid Remains Strong

For patients with T-scores between -2.5 and -3.0 and no prior fracture, zoledronic acid offers proven 70% vertebral fracture reduction with one annual infusion, avoidance of the CV black-box warning, and a cost roughly 50 times lower than romosozumab. The HORIZON-PFT extension study (6 years, N=1,233) demonstrated sustained anti-fracture efficacy without increased atypical femur fracture risk through year six [12].

After a Bisphosphonate Course: Can You Switch to Romosozumab?

Patients who complete three to five years of zoledronic acid and remain at high risk may benefit from transitioning to romosozumab. The STRUCTURE trial (N=436) compared romosozumab vs teriparatide in women previously treated with alendronate and found that romosozumab produced greater hip BMD gains (2.6% vs -0.6% at 12 months, P<0.001) [13]. No equivalent trial exists specifically after zoledronic acid, but the mechanism suggests similar benefit since bisphosphonates suppress resorption without building new bone.

Endocrinologist Dr. E. Michael Lewiecki, writing in the Journal of Clinical Endocrinology and Metabolism, described the sequencing principle this way: "The greatest gains in BMD are achieved when anabolic therapy is used before antiresorptive therapy, because prior antiresorptive exposure blunts the anabolic response" [14].

After Romosozumab: You Must Follow With Anti-Resorptive Therapy

Stopping romosozumab without transitioning to an anti-resorptive causes rapid BMD loss within six months. The FDA label explicitly states that anti-resorptive therapy should follow the 12-month course [2]. Zoledronic acid is a common choice here: one infusion per year is easier to maintain than daily or weekly oral bisphosphonates, and ARCH used alendronate in the comparator arm only because the trial predated widespread anabolic-first sequencing recommendations.

Cost, Access, and Insurance Coverage

Romosozumab carries a wholesale acquisition cost of approximately $21,000 for a 12-month course (12 injections at ~$1,750 each) as of 2024. Zoledronic acid, available as generic since 2017, costs $300 to $400 per annual infusion. Medicare Part B covers zoledronic acid infusions in outpatient settings; romosozumab is covered under Part D or Part B depending on site of administration.

Prior authorization for romosozumab typically requires documented very-high fracture risk, often a prior fracture or T-score at or below -3.0. In a 2023 survey of 420 endocrinologists and rheumatologists published in Osteoporosis International, 67% reported that insurance denial was the primary barrier to prescribing romosozumab to eligible patients [15].

Tolerability and Common Side Effects

Both drugs are generally well tolerated, but their side-effect profiles differ enough to affect patient selection.

Zoledronic Acid Side Effects

The most common adverse event is an acute-phase reaction occurring within 72 hours of the first infusion: fever, myalgia, arthralgia, and headache in roughly 32% of first-time recipients vs 7% after the second infusion [1]. Pre-treatment with acetaminophen 1,000 mg reduces severity. Osteonecrosis of the jaw (ONJ) is rare (estimated 1 in 10,000 to 1 in 100,000 patient-treatment years in osteoporosis dosing) and atypical femur fracture risk rises modestly after five years of continuous use [9].

Romosozumab Side Effects

Injection-site reactions occur in about 5% of patients [2]. The cardiovascular signal described above is the primary safety concern. ONJ and atypical femur fracture have been reported rarely, with rates similar to bisphosphonate therapy in pooled trial data [2].

Practical Clinical Decision Aid

Choosing between zoledronic acid and romosozumab comes down to five patient-specific variables:

1. Fracture risk category. Very-high risk favors romosozumab first. High (not very-high) risk can start with zoledronic acid.
2. Cardiovascular history. A myocardial infarction or stroke within the past 12 months is a contraindication to romosozumab [2].
3. Renal function. CrCl <35 mL/min rules out zoledronic acid; romosozumab may be used with caution in moderate CKD.
4. Prior therapy. Patients completing a bisphosphonate course who remain high-risk may gain more from a romosozumab course than from continued bisphosphonate use.
5. Cost and adherence capacity. Monthly injections over 12 months require patient commitment; a single annual infusion is simpler for many.

Should I Switch from Reclast to Evenity?

Switching from zoledronic acid to romosozumab is medically appropriate under specific conditions and is supported by both guideline recommendations and mechanistic rationale.

Who Is a Good Candidate for the Switch?

A patient who has completed three to five years of zoledronic acid and still meets very-high fracture risk criteria (new fracture on therapy, worsening T-score, or T-score remaining at or below -3.0) may benefit from a romosozumab course. Because bisphosphonates linger in bone mineral for years, the residual anti-resorptive effect means romosozumab's anabolic component can work without a competing resorption surge when the drug stops. This is mechanistically favorable, though direct randomized data comparing zoledronic acid switchers to de-novo starters are not yet available.

Timing the Switch

The standard practice is to wait until the next annual zoledronic acid infusion is due before starting romosozumab. There is no mandatory washout period. Starting romosozumab while zoledronic acid is still pharmacologically active does not appear harmful based on available pharmacokinetic data, but the theoretical concern is that residual bisphosphonate may blunt the anabolic response somewhat.

What Comes After the Switch?

After the 12-month romosozumab course, transitioning back to zoledronic acid makes clinical and logistical sense: the patient is already established with that infusion workflow, and ARCH demonstrates that anti-resorptive consolidation after romosozumab preserves BMD gains for at least two additional years [3]. The American Society for Bone and Mineral Research (ASBMR) Task Force notes that denosumab is also an acceptable follow-on agent but carries a rebound fracture risk if discontinued without transitioning to a bisphosphonate [16].